Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994926 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment
A Early Phase 1 study, sponsored by Battelle Memorial Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03994926 is a Early Phase 1 study that was terminated before completion, run by Battelle Memorial Institute. The registered enrollment target is 3 participants.
The verdict
NCT03994926, a Early Phase 1 study, was terminated before completion, sponsored by Battelle Memorial Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).
Interventions
- DEVICE Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye
- DRUG Cannabis cigarette - 4.0% THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2020-03-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03994926
The ClinicalTrials.gov registry entry for NCT03994926 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Battelle Memorial Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye is the first listed.
NCT03994926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03994926 about?
NCT03994926 is a clinical study titled "Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment". The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self...
What is the current status of trial NCT03994926?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-03. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03994926?
The interventions under investigation include: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye (DEVICE), Cannabis cigarette - 4.0% THC (DRUG).
Who is sponsoring clinical trial NCT03994926?
This trial is sponsored by Battelle Memorial Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.